<DOC>
	<DOCNO>NCT01956409</DOCNO>
	<brief_summary>The application FCH PET breast cancer diagnosis report . We hypothesize FCH reveals choline metabolic profile breast cancer , show similar pathophysiological mechanism choline proton MRS , study goal : 1 . To investigate compare diagnostic performance proton MRS FCH PET localize finding mammography breast ultrasound . 2 . To investigate whether FCH PET finding correlate choline signal proton MRS. 3 . To evaluate choline , water lipid signal proton MRS , FCH PET associate factor related clinical outcome prognosis- , molecular marker , tumor staging , histologic grade breast cancer . 4 . For localized advanced breast cancer , investigate treatment response NAC use proton MRS FCH PET , evaluate modality sensitive . 5 . To investigate usefulness FCH PET whole body stag breast cancer patient .</brief_summary>
	<brief_title>Proton MR Spectroscopy 18F-Fluorocholine PET Breast Cancer Diagnosis</brief_title>
	<detailed_description>In recent year , application 18F-FDG PET ( positron emission tomography ) MRI breast lesion diagnosis emerge . Imbriaco et al compare diagnostic performance 18F-FDG PET MRI suspicious breast lesion , PET show sensitivity 80 % specificity 100 % ; MRI reveal sensitivity 95 % specificity 98 % . Lim et al studied 18F-FDG PET-CT MRI monitor treatment response breast cancer patient receive NAC , sensitivity 70 % specificity 72 % , detect treatment response earlier conventional imaging . However , 18F-FDG tumor specific , search alternative tracer agent tumor biomarker necessary . 18F-Fluorocholine ( FCH ) , choline analog , use diagnosis prostate cancer , hepatocellular carcinoma ( HCC ) , bronchioloalveolar carcinoma , brain tumor , since malignant tumor show high choline metabolite benign lesion ; report FCH PET show high sensitivity ( 88-94 % ) 18F-FDG PET ( 59-68 % ) detecting HCC . FCH PET use stag prostate cancer , FCH PET-CT provide sufficient information management accuracy 88 % .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women age 2075 year old . localize finding mammography breast ultrasound recent 3 month receive breast biopsy excision finding ; recently diagnose LABC receive NAC . unable cooperate examination pregnant plan pregnant estimate GFR ( eGFR ) &lt; 60 ml/min/1.73m2 recent acute renal failure , past history renal dialysis . Past history claustrophobia Past history anaphylactoid reaction MRI contrast agent PET tracer agent . cardiac pacemaker , aneurysmal clip , mechanical valve replacement , recently apply coronary artery stent ( &lt; 2 month ) . Past history breast cancer malignancy ( treat within 5 year ) . lactating .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>breast neoplasm</keyword>
	<keyword>18F-FCH PET</keyword>
	<keyword>MRI</keyword>
</DOC>